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The Fourth External Review of the
Special Programme for Research and
Training in Tropical Diseases (TDR) took
place between February 2005 and May
2006, led by Professor Abdallah Daar and
colleagues [1]. Since its establishment in
1978, TDR has drawn heavily on the
recommendations of its external reviews in
order to shape its strategy and structures
going forward [2]. This fourth review was
particularly pertinent given the dramati-
cally changed global health landscape that
TDR finds itself in at the beginning of the
21st century.
Having experienced great success in
research capacity strengthening and prod-
uct development for neglected diseases
over the years, TDR now shares the space
with many other national and multilateral
agencies in these two fields. At the time of
the Fourth External Review, it needed to
carefully examine, consult on, and reshape
its strategy in order to work effectively in
this new milieu.
The two articles in this issue of PLoS
Neglected Tropical Diseases summarise the
Fourth External Review [1] and map out
the response of TDR in its new Ten Year
Strategy and Business Plan [3]. The plan
was approved by TDR’s Joint Coordinating
Board(JCB)inJune2007,andthestrategyis
now in the first stages of implementation,
which began in January 2008.
The Fourth External Review mapped
out the strengths and weaknesses of TDR.
From my point of view as the President and
Chief Executive Officer of a Medical
Research Council (MRC) in a disease-
endemic country (South Africa), the re-
view’s assessment of TDR’s strengths and
weaknesses seemed valid and insightful.
Daar and his colleagues then recommend-
ed that TDR undertake a major re-
orientation and stakeholder engagement
exercise, and reconfigure its work into four
functional areas: stewardship, research
advocacy, and coordination; research and
development for physical products; ex-
panded intervention research; and research
capacity strengthening for the future.
TDR has largely followed these recom-
mendations under the banner of its new
vision—‘‘to foster an effective global
research effort on infectious diseases of
poverty in which disease-endemic coun-
tries play a pivotal role’’ [2].
The new vision embodies the review
recommendation of an increased emphasis
on ‘‘needy populations’’ as compared to
‘‘neglected diseases’’. The vision also in-
cludes a move towards more transdisciplin-
ary work, including addressing the social as
well as biomedical determinants of health.
The strategy illustrates this new ap-
proach through a diagram of the research
continuum that stretches from basic re-
search through product development to
intervention and implementation research
and ultimately health impact [3]. Within
this continuum, TDR will strategically
focus on knowledge management (linked
to its stewardship function); capacity
building (linked to its empowerment func-
tion); and neglected areas in research.
The aim of this focus is to ensure that
TDR finds a role for itself filling gaps in
the new global landscape, and forging
strong partnerships with other global
players as well as with research institutions
in disease-endemic countries. Thus in
South Africa, TDR has forged strong
collaborations in the past few years on
drug availability studies for tuberculosis
drugs, as well as phase III clinical trials of
treatment shortening regimens for tuber-
culosis infection. The strategy also shows
how TDR’s new functions map out against
the research continuum, with expert
scientific advisory committees convened
to support the three functions of steward-
ship, empowerment, and research ‘‘busi-
ness line activities’’.
TDR is implementing the review rec-
ommendation that ‘‘all stakeholders [sup-
port] TDR to evolve and grow to a
renewed mandate’’ [1] by becoming more
responsive to stakeholder issues, including
changes in the processes of the JCB in
order to respond to wider constituencies
than are represented on the JCB. The
review criticism that TDR was ‘‘over-
administrated and under-managed’’ [1] is
being addressed in part through decentra-
lising managerial and administrative au-
thority, and also through initiatives at the
World Health Organization (the legal
executing agency for TDR) to streamline
its excessive bureaucracy. However,
TDR’s governing bodies chose not to
decentralise its activities to regional cen-
tres. TDR and the co-sponsoring agencies
will actively support the development of
national research policies.
In the past ten years, TDR has
established many product development
activities, but will in future focus on
research and development for physical
products for very neglected diseases that
others are not addressing adequately.
TDR will remain involved in basic
hypothesis-driven research, but will in-
crease its emphasis on expanded interven-
tion research where there are many
diverse actors. Once drugs and diagnostics
are developed, research is needed to
examine their impact on individual and
population health, which in turn is depen-
dent on ‘‘micro’’ and ‘‘macro’’ factors.
The micro factors include the behavioural
determinants of medicine use and adher-
ence. The macro factors include the health
systems that are necessary to deliver these
medicines, including the health economics
of sustainable supply systems. Operational
research is needed to evaluate and im-
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In conclusion then, from the perspective
of the manager of a national research
institution in a disease-endemic country,
TDR seems poised and able to realize the
vision quoted above. It has already
established collaborations with my re-
search institution, the MRC, that involve
equal partnerships with MRC scientists
playing a critical role in both phase II and
III clinical trials. We look forward to long
and expanded collaborations between
TDR and all disease-endemic countries
in understanding the biomedical and
social pathogenesis of infectious disease,
and developing new tools for diagnosis and
treatment of those diseases.
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